Extracellular RNAs are gaining clinical interest as biofluid-based noninvasive markers for diseases, especially cancer. In particular, derivatives of transfer RNA (tRNA) are emerging as a new class of small-noncoding RNAs with high biomarker potential. We and others previously reported alterations in serum levels of specific tRNA halves in disease states including cancer. Here, we explored seminal fluid for tRNA halves as potential markers of prostate cancer. We found that 5' tRNA halves are abundant in seminal fluid and are elevated in prostate cancer relative to noncancer patients. Importantly, most of these tRNA halves are also detectable in prostatic tissues, and a subset were increased in malignant relative to adjacent normal tissue. These findings emphasize the potential of 5' tRNA halves as noninvasive markers for prostate cancer screening and diagnosis and provide leads for future work to elucidate a putative role of the 5' tRNA halves in carcinogenesis.
Keyphrases
- prostate cancer
- radical prostatectomy
- rna seq
- end stage renal disease
- papillary thyroid
- single cell
- chronic kidney disease
- gene expression
- ejection fraction
- prognostic factors
- benign prostatic hyperplasia
- human health
- electronic health record
- machine learning
- deep learning
- patient reported
- patient reported outcomes
- artificial intelligence
- data analysis
- electron transfer